

# ISPE Europe Virtual Annual Conference 2020

## COVID-19 and after

Impact on Innovation, Production, Quality and Supply chain

16 - 17 September 2020  
chair: Jean Francois Duliere, France

### 16 September 2020

08.30 - 08.45	Welcome, Jean Francois Duliere
08.45 - 09.10	<b>ISPE in Europe - Mission, Vision, Strategy</b> Thomas Zimmer, ISPE VP European Operations
<b>Track 1</b>	<b>Factories of the future - Back up manufacturing, contingency plans, more local API production?</b>
	<i>chairs: Gert Moelgaard, Marick Paris Cadet</i>
09.10 - 09.35	<b>Sanofi category winner 2020</b> Speaker tbd
09.35 - 10.00	<b>Continuous manufacturing</b> John Groskoph, Executive Director, Global CMC, Pfizer
10.00 - 10.25	<b>Continuous manufacturing - a real operational example in the API world-Lilly</b> Speaker tbd
10.25 - 11.00	Interaction with Exhibitors
11.00 - 11.25	<b>Vaccines for the World - Insights into Design and Execution of a BSL2 Fill-Finish Facility</b> Matthias Angelmaier, Product Manager Isolator Technology, Bosch Rutger Vandiest, Sr. Director - Head of Sales, Bavarian Nordic Daryn Jenkins, Managing Director, EMEA, IPS
11.25 - 11.50	<b>Cell Therapy Journey from Research to Clinical Manufacturing</b> Christina Dragsbaek Ravn, Project Manager, Novo Nordisk Henriette Schubert, Managing Consultant, NNE

11.50 - 12.15	<b>Novel Therapies : Developing a single use adenovirus vector process through public-private collaboration</b> Dr. Sofiya Fedosyuk, Vaccine developer at Jenner Institute, UK Youness Cherradi, PhD, Senior Process Development Scientist at Merck
12.15 - 12.40	<b>ISPE Baseline Guide Water and Steam</b> Speaker from DACH affiliate tbd
12.40 - 13.00	Q&A Session with all speakers
13.00 - 13.30	Interaction with Exhibitors
<b>Track 2</b>	<b>Industrie's and regulators view on COVID-19 - impact on industry and regulation</b>
	<i>chairs: Christian Woelbeling and Teresa Minero</i>
13.30 - 13.55	<b>ISPE Global Strategy after COVID 19 - what is important</b> Tim Howard - President and CEO of ISPE
13.55 - 14.20	<b>FDA input on COVID-19 - Learnings and consequences</b> Carmelo Rosa and Juan Melendez, FDA
14.20 - 14.45	<b>Inhouse COVID Testing</b> Tobias Haas, Merck Healthcare KGaA, Global Head of Analytical Development
14.45 - 15.10	<b>Regulatory info sharing from Europe related to COVID-19</b> Jacques Morenas, ANSM
15.10 - 15.45	Interaction with Exhibitors
15.45 - 16.10	<b>How can Pharma 4.0 help to manage the COVID crisis?</b> Christian Woelbeling, chair ISPE Special Interest Group Pharma 4.0
16.10 - 17.30	<b>Panel Discussion with Speakers and Regulators</b> Introduction Johanna Gouws (WHO) - 10 min
<b>17 September 2020</b>	
<b>Track 3</b>	<b>Quality management in crisis times - relevant regulation for industry, how to protect workers and products</b>
	<i>chairs: Cristina Mazo, Eva Montana, Jean Francois Duliere</i>

09.10 - 09.35	<b>Practical Implementation of Medical Devices, Apps and Digitisation - Company Perspective</b> María Jesús Salido, SocialDiabetes, S.L.
09.35 - 10.00	<b>"ICH Q 13 and FDA Guidance on continuous manufacturing - A jumpstart for new Quality Management Principles</b> Ron Ogilvie, Pfizer
10.00 - 10.25	<b>GMP Inspection Reliance: Experience to Date and Future Expectations</b> Anne Hayes & C. Schaerer & Jacques Morenas & Mark Birse
10.25 - 11.00	Interaction with Exhibitors
11.00 - 11.25	<b>"Virtual inspections - an option after Covid-19?</b> Anne Hayes & C. Schaerer & Jacques Morenas & Mark Birse
11.25 - 12.15	<b>REGULATORY PANEL SESSION</b> <b>Virtual Inspections and GMP Reliance</b> <b>10 min intro by 4-5 Regulators</b>
12.15 - 13.00	<b>REGULATORY PANEL SESSION</b> <b>Current situation on Drug shortages - COVID: one challenge more!</b>
13.00 - 13.30	Interaction with Exhibitors
<b>Track 4</b>	<b>New trends in CQV and impact on project delivery in times of Corona crisis</b>

*chairs: Michael Atzor, David Estape; Michael Hell*

13.30 - 13.50	<b>New issue of ISPE guideline and impact to C&amp;Q.</b> Hazem El-Eskandarani, P.E. Project Director ( J&J ) Block, Program manager ( Bayer AG )	Joerg
13.50 - 14.10	<b>Data Integrity by Design in Qualification</b> Fritz Roeder, Merck Healthcare KGaA	
14.10 - 14.30	<b>Engineering Change Management</b> Adnan Abosh, Associate Director, Equipment/Facility qualification, Apotex Inc	
14.30 - 14.50	<b>FAT execution in times of COVID-19</b> Patrick Sullivan (CRB) and Douglas Arnold (Merck)	
14.50 - 15.10	<b>Accelerating Project Execution Utilising GEP and Collaboration with Suppliers.</b> Lars Hovmand-Lyster, Novo Nordisk	
15.10 - 15.45	Interaction with Exhibitors	
15.45 - 16.05	<b>How to Interpret and Manage CQV Requirements – a Suppliers Viewpoint.</b> Matthias Naser, Optima Pharma GmbH	
16.05 - 16.25	<b>Adaptive Qualification Approach for Cleaning Systems with Fuzzy Control Logic</b> Ralf Kretzschmar, CEO, Belimed Life Science AG	

16.25 - 16.45	<b>The use of lean thinking in the execution of CQV for a cell and gene therapy and the benefit of applying single piece flow and visual management in the execution.</b> Joonleong Ng (Pierre Winnepenninckx contact person)
16.45 - 17.05	<b>Risk - and Lifecycle Management of Biopharmaceutical Operations: ICH Q12 on Legacy Products.</b> José C. Menezes, Madalena R. Testas, Sofia T. Santos, Marco Strohmeier
17.05 - 17.30	Q&A Session with all speakers